aTyr Pharma, Inc.(US:ATYR) Prnewswire·2025-09-17 13:03Core Viewpoint - aTyr Pharma, Inc. experienced a significant decline in share price, dropping over 80% following the announcement that its late-stage study of efzofitimod for pulmonary sarcoidosis did not achieve its primary endpoint [1] Company Summary - The company reported on September 15, 2025, that its clinical trial for efzofitimod, aimed at treating pulmonary sarcoidosis, failed to meet its main goal [1] - This failure in the late-stage study has led to a drastic decrease in investor confidence, reflected in the sharp decline in share price [1] Industry Summary - The incident highlights the volatility and risks associated with clinical trials in the biopharmaceutical industry, particularly for companies developing treatments for interstitial lung diseases [1] - The failure of a late-stage study can have immediate and severe financial implications for companies in this sector, affecting stock performance and investor sentiment [1]